share_log

Sera Prognostics | 8-K: SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS

SEC ·  Mar 19 20:14

Summary by Moomoo AI

Sera Prognostics reported Q4 2024 revenue of $24,000, down from $41,000 in Q4 2023, with a net loss of $8.6M compared to $7.9M in the prior year. Operating expenses increased 6% to $9.4M. For full year 2024, revenue was $77,000 with a net loss of $32.9M, improved from $36.2M loss in 2023.The company's PRIME study showed promising results, demonstrating a 25% reduction in neonatal morbidity and mortality index and an 18% reduction in neonatal hospital stay length. The study results were presented at the Society for Maternal Fetal Medicine 2025 Pregnancy Meeting.In February 2025, Sera raised $57.5M through a public follow-on offering, extending its cash runway through 2028. The funds will support commercial expansion in the US, preparation for EU market entry, and additional studies for broader adoption of its PreTRM test, including potential FDA submission.
Sera Prognostics reported Q4 2024 revenue of $24,000, down from $41,000 in Q4 2023, with a net loss of $8.6M compared to $7.9M in the prior year. Operating expenses increased 6% to $9.4M. For full year 2024, revenue was $77,000 with a net loss of $32.9M, improved from $36.2M loss in 2023.The company's PRIME study showed promising results, demonstrating a 25% reduction in neonatal morbidity and mortality index and an 18% reduction in neonatal hospital stay length. The study results were presented at the Society for Maternal Fetal Medicine 2025 Pregnancy Meeting.In February 2025, Sera raised $57.5M through a public follow-on offering, extending its cash runway through 2028. The funds will support commercial expansion in the US, preparation for EU market entry, and additional studies for broader adoption of its PreTRM test, including potential FDA submission.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 344

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
NanoVibronix
NAOV
4.4500
Outset Medical
OM
11.280
Autonomix Medical
AMIX
2.190
Modular Medical
MODD
1.050
ReShape Lifesciences
RSLS
0.6960
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
Fed rate cut expectations for 2025 intensify. What’s your market outlook?
42%
58%
Bullish
Bearlish
1143 votes
FOMC Press Conference, March 19, 2025